Phase 2 Trial of LACTIN-V in Women at High Risk of HIV Acquisition

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 10, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

March 31, 2023

Conditions
Bacterial VaginosisHIV Infections
Interventions
DRUG

LACTIN-V

administered vaginally

DRUG

Placebo

administered vaginally

Trial Locations (1)

4066

FRESH (Females Rising through Education, Support and Health) Clinical Research Site, Durban

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

University of KwaZulu

OTHER

collaborator

Harvard University

OTHER

collaborator

Aurum Institute

OTHER

collaborator

Health Systems Trust

OTHER

collaborator

Osel, Inc.

INDUSTRY

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

University of California, San Francisco

OTHER